More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

UK Prime Minister Theresa May faces external and internal hurdles and the possibility of a “no deal,” meaning the UK would leave the European Union (EU) without a Brexit agreement. What is the impact for pharmaceutical companies in terms of...

Oncology is the largest therapeutic sector in the global and US pharmaceutical markets with US spending on cancer drugs reaching almost $50 billion in 2017. Following that trend, CMDOs and CMOs are investing in high-potency development and...

Novartis’ Sandoz, Teva, Perrigo and Mylan are among the companies reporting lower revenues in their generics businesses, principally due to performance in the US market. With these companies revamping their strategies to address changing market...

Emerging pharma companies are an important source of product innovation for the pharmaceutical industry, so which companies are making the mark? DCAT Value Chain Insights takes an inside look. For new molecular entities approved by the US Food and...

The Pharmaceutical Research and Manufacturers of America (PhRMA) has released a new policy position that delinks supply-chain payments as a means to improve patient affordability. The policy is in response to an earlier blueprint issued by the US...

Strategic partnerships are key in delivering value in supply management, so what are some ways in which companies are collaborating to achieve such value? DCAT Sharp Sourcing, which was held in New Brunswick, New Jersey in late June, featured...

Pfizer announced last week that it will reorganize into three businesses, an Innovative Medicines business, an Established Medicines unit, and a Consumer Healthcare business. So what is the restructuring all about? This is the second...

A recent European Medicines Agency (EMA) survey shows that marketing authorization holders for more than half (58%) of the 694 centrally authorized products in the UK are on track with their regulatory planning to ensure that their marketing...

As we reach the mid-point of 2018, how are approvals of new molecular entities faring? As of the end of June, the FDA had approved 20 NMEs, a similar number as approved this time last year when the FDA had approved 23 NMEs by mid-year with an...